Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Sacubitril-valsartan didn't improve exercise fitness in nonobstructive hypertrophic cardiomyopathy (nHCM) patients, but it did shrink heart muscle thickness. A 50-week randomized trial found no significant difference in peak oxygen uptake between the drug and placebo groups. However, the drug was linked to meaningful reductions in heart wall thickness and left ventricular mass — structural changes that could still matter clinically.
A 50-week double-blind randomized trial tested sacubitril-valsartan — a drug combo widely used in heart failure — in adults with nonobstructive hypertrophic cardiomyopathy (nHCM) and reduced exercise capacity. The primary goal was to see if the drug could boost peak oxygen uptake (pVO2), a key measure of exercise fitness. The result: no significant difference in pVO2 between the drug and placebo groups, despite near-perfect treatment compliance (96%) in both arms.
But the story doesn't end there. Patients on sacubitril-valsartan showed notable structural heart improvements — a 4.7 mm reduction in interventricular septal thickness and a 22.5 g/m² drop in left ventricular mass index. A composite score of cardiac parameters also improved significantly in the treatment group. Whether these structural changes translate into better long-term outcomes for nHCM patients remains an open question.
Key Takeaways:
Why it matters: nHCM is a common but under-treated form of hypertrophic cardiomyopathy with limited therapeutic options. While sacubitril-valsartan didn't hit its primary endpoint, its cardiac remodeling effects keep the door open for further investigation into whether structural benefits could yield meaningful clinical gains over time.
